UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 425

Sortiert nach

Infiltrating stromal immune cells in inflammatory breast cancer are associated with an improved outcome and increased PD-L1 expression

Breast cancer research : BCR, 2019-02, Vol.21 (1), p.28-28, Article 28

2019

Link zum Volltext

Verfügbarkeit prüfen

Early vedolizumab trough levels predict mucosal healing in inflammatory bowel disease: a multicentre prospective observational study

Alimentary Pharmacology & Therapeutics (Suppl), 2018-04, Vol.47 (7), p.906-912

2018

Link zum Volltext

Verfügbarkeit prüfen

Quality outcome measures project in IBD: a proof-of-concept benchmarking study in three Belgian IBD units

Acta gastro-enterologica belgica, 2023-10, Vol.86 (4), p.521-526

2023

Link zum Volltext

Verfügbarkeit prüfen

Editorial: antigenic response to CT‐P13 and infliximab originator in IBD shows similar epitope recognition—evidence from basic science supports safe switching to biosimilars

Alimentary pharmacology & therapeutics, 2018-09, Vol.48 (5), p.574-575

2018

Link zum Volltext

Verfügbarkeit prüfen

Échanges et communications, I: Mélanges offerts à Claude Lévi-Strauss à l'occasion de son 60ème anniversaire

2020

Link zum Volltext

Verfügbarkeit prüfen

Detection and prognostic significance of circulating tumour cells in patients with metastatic breast cancer according to immunohistochemical subtypes

British journal of cancer, 2014-01, Vol.110 (2), p.375-383

2014

Link zum Volltext

Verfügbarkeit prüfen

N03 Introducing video consultations as part of an IBD tight monitoring care pathway: interim results of the INTERACTION project

Journal of Crohn's and colitis, 2023-01, Vol.17 (Supplement_1), p.i1038-i1039

2023

Link zum Volltext

Verfügbarkeit prüfen

Pratiquer les sciences sociales au Maghreb

Centre Jacques-Berque, 2014

2014

Link zum Volltext

Verfügbarkeit prüfen

The nocebo effect: a clinical challenge in the era of biosimilars

Expert review of clinical immunology, 2018-09, Vol.14 (9), p.739-749

2018

Link zum Volltext

Verfügbarkeit prüfen

P285 A retrospective observational study on the effectiveness and safety of vedolizumab with or without budesonide induction therapy among patients with moderate-to-severe Crohn’s disease

Journal of Crohn's and colitis, 2021-05, Vol.15 (Supplement_1), p.S317-S319

2021

Link zum Volltext

Verfügbarkeit prüfen

N02 PREVIEW study: Factors associated with willingness to switch from intravenous to subcutaneous formulations of CT-P13 and vedolizumab in patients with Inflammatory Bowel Disease

Journal of Crohn's and colitis, 2021-05, Vol.15 (Supplement_1), p.S608-S609

2021

Link zum Volltext

Verfügbarkeit prüfen

OP09 Patient reported outcomes reflect histologic disease activity in patients with Ulcerative Colitis: Interim analysis of the APOLLO study

Journal of Crohn's and colitis, 2021-05, Vol.15 (Supplement_1), p.S008-S009

2021

Link zum Volltext

Verfügbarkeit prüfen

N06 Patient-reported outcomes in daily clinical care of patients with inflammatory bowel diseases

Journal of Crohn's and colitis, 2019-01, Vol.13 (Supplement_1), p.S559-S559

2019

Link zum Volltext

Verfügbarkeit prüfen

DOP81 Quality improvement by semi-automated benchmarking of a core outcome quality indicator set in Inflammatory Bowel Disease: A multicentric feasibility study

Journal of Crohn's and colitis, 2021-05, Vol.15 (Supplement_1), p.S112-S112

2021

Link zum Volltext

Verfügbarkeit prüfen

N01 Type of patient education impacts the willingness to switch from an IV to SC of a biological in patients with Inflammatory Bowel Disease: A multicentre, comparative study

Journal of Crohn's and colitis, 2022-01, Vol.16 (Supplement_1), p.i617-i618

2022

Link zum Volltext

Verfügbarkeit prüfen

P782 Ustekinumab in Ulcerative colitis: a real-life effectiveness study across multiple Belgian centers (SULTAN)

Journal of Crohn's and colitis, 2023-01, Vol.17 (Supplement_1), p.i916-i917

2023

Link zum Volltext

Verfügbarkeit prüfen

DOP48 Faecal microbiota transplantation in active Ulcerative Colitis: Key lessons from a randomized controlled trial halted for futility

Journal of Crohn's and colitis, 2024-01, Vol.18 (Supplement_1), p.i159-i160

2024

Link zum Volltext

Verfügbarkeit prüfen

P530 Ultra-proactive therapeutic drug monitoring incorporating infliximab point-of-care testing with ad hoc dose adjustment reduces C-reactive protein levels in patients with IBD during infliximab maintenance treatment

Journal of Crohn's and colitis, 2019-01, Vol.13 (Supplement_1), p.S378-S378

2019

Link zum Volltext

Verfügbarkeit prüfen

OP03 Standardized faecal microbiota transplantation with microbiome-guided donor selection in active UC patients: A randomized, placebo-controlled intervention study

Journal of Crohn's and colitis, 2022-01, Vol.16 (Supplement_1), p.i003-i004

2022

Link zum Volltext

Verfügbarkeit prüfen

OP13 Postoperative Crohn’s disease recurrence: unanswered questions and future directions in diagnosis, pathophysiology, prevention and treatment. Conclusions from the 8th ECCO Scientific workshop

Journal of Crohn's and colitis, 2023-01, Vol.17 (Supplement_1), p.i18-i19

2023

Link zum Volltext

Verfügbarkeit prüfen

P921 FMT in UC is associated with a decrease in Bacteroides-2 enterotype and response with baseline RNA and microbiota signatures

Journal of Crohn's and colitis, 2023-01, Vol.17 (Supplement_1), p.i1029-i1031

2023

Link zum Volltext

Verfügbarkeit prüfen

P440 Early changes in the pharmacokinetic profile of vedolizumab-treated patients with inflammatory bowel disease may predict response after dose optimisation

Journal of Crohn's and colitis, 2018-01, Vol.12 (supplement_1), p.S327-S328

2018

Link zum Volltext

Verfügbarkeit prüfen

P564 Significant reduction of admission time at the IBD infusion unit by an e-health pre-admission assessment and order system for intravenous therapy

Journal of Crohn's and colitis, 2019-01, Vol.13 (Supplement_1), p.S396-S396

2019

Link zum Volltext

Verfügbarkeit prüfen

P362 Prospective study of phArmaCokinetics of InFliximab during induction in patients with Crohn’s disease and ulcerative colitis (PACIFIC)

Journal of Crohn's and colitis, 2020-01, Vol.14 (Supplement_1), p.S343-S344

2020

Link zum Volltext

Verfügbarkeit prüfen

P635 Superior outcomes with early biologic-combination treatment in Crohn’s Disease: Data from an international inception cohort

Journal of Crohn's and colitis, 2020-01, Vol.14 (Supplement_1), p.S527-S528

2020

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 425

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(158)
Mit Volltextzugriff
(414)

Publikationsform

Artikel
(176)
Buchkapitel
(136)
Reviews
(85)
Berichte
(19)
Bücher
(4)
Texte
(3)
Tagungsberichte
(2)

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Infiltrating stromal immune cells in inflammatory breast cancer are associated with an improved outcome and increased PD-L1 expression

Early vedolizumab trough levels predict mucosal healing in inflammatory bowel disease: a multicentre prospective observational study

Quality outcome measures project in IBD: a proof-of-concept benchmarking study in three Belgian IBD units

Editorial: antigenic response to CT‐P13 and infliximab originator in IBD shows similar epitope recognition—evidence from basic science supports safe switching to biosimilars

Échanges et communications, I: Mélanges offerts à Claude Lévi-Strauss à l'occasion de son 60ème anniversaire

Detection and prognostic significance of circulating tumour cells in patients with metastatic breast cancer according to immunohistochemical subtypes

N03 Introducing video consultations as part of an IBD tight monitoring care pathway: interim results of the INTERACTION project

Pratiquer les sciences sociales au Maghreb

The nocebo effect: a clinical challenge in the era of biosimilars

P285 A retrospective observational study on the effectiveness and safety of vedolizumab with or without budesonide induction therapy among patients with moderate-to-severe Crohn’s disease

N02 PREVIEW study: Factors associated with willingness to switch from intravenous to subcutaneous formulations of CT-P13 and vedolizumab in patients with Inflammatory Bowel Disease

OP09 Patient reported outcomes reflect histologic disease activity in patients with Ulcerative Colitis: Interim analysis of the APOLLO study

N06 Patient-reported outcomes in daily clinical care of patients with inflammatory bowel diseases

DOP81 Quality improvement by semi-automated benchmarking of a core outcome quality indicator set in Inflammatory Bowel Disease: A multicentric feasibility study

N01 Type of patient education impacts the willingness to switch from an IV to SC of a biological in patients with Inflammatory Bowel Disease: A multicentre, comparative study

P782 Ustekinumab in Ulcerative colitis: a real-life effectiveness study across multiple Belgian centers (SULTAN)

DOP48 Faecal microbiota transplantation in active Ulcerative Colitis: Key lessons from a randomized controlled trial halted for futility

P530 Ultra-proactive therapeutic drug monitoring incorporating infliximab point-of-care testing with ad hoc dose adjustment reduces C-reactive protein levels in patients with IBD during infliximab maintenance treatment

OP03 Standardized faecal microbiota transplantation with microbiome-guided donor selection in active UC patients: A randomized, placebo-controlled intervention study

OP13 Postoperative Crohn’s disease recurrence: unanswered questions and future directions in diagnosis, pathophysiology, prevention and treatment. Conclusions from the 8th ECCO Scientific workshop

P921 FMT in UC is associated with a decrease in Bacteroides-2 enterotype and response with baseline RNA and microbiota signatures

P440 Early changes in the pharmacokinetic profile of vedolizumab-treated patients with inflammatory bowel disease may predict response after dose optimisation

P564 Significant reduction of admission time at the IBD infusion unit by an e-health pre-admission assessment and order system for intravenous therapy

P362 Prospective study of phArmaCokinetics of InFliximab during induction in patients with Crohn’s disease and ulcerative colitis (PACIFIC)

P635 Superior outcomes with early biologic-combination treatment in Crohn’s Disease: Data from an international inception cohort

Suchergebnisse filtern